Thomas H. Sisson, M.D.
Clinical Associate Professor of Internal Medicine
Division of Pulmonary & Critical Care Medicine
University of Michigan Health System
Thomas H. Sisson, M.D.
Clinical Associate Professor of Internal Medicine
Division of Pulmonary & Critical Care Medicine
University of Michigan Health System
1150 W. Medical Center Drive, MSRB III 6301
Ann Arbor, MI 48109-5642
Phone: 734-936-5047; Fax: 734-764-4556
Title and Contents Page 1
Education and Training Page 2
Certification and Licensure Page 2
Academic, Administrative, and Clinical Appointments Page 2
Research Interests Page 3
Grants Page 3-4
Honors and Awards Page 4
Memberships in Professional Societies Page 4
Teaching Page 5-6
Committee, Organizational, and Volunteer Service Page 6
Visiting Professorships, Seminars, and Extramural Invited Presentations Page 6
Bibliography Page 7-11
Education & Training
Education:
9/1982 – 4/1987 B.S., University of Michigan, School of Literature, Science and Arts
Ann Arbor, MI
9/1988 – 4/1992 M.D., University of Michigan, Ann Arbor, MI
Training:
7/1992 – 7/1993 Internship, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI
7/1993 – 7/1995 Residency, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI
7/1995 – 7/1998 Fellow, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI
Certification and Licensure
1997- Michigan Medical License Exp.1/31/2007
1997- Michigan Board of Pharmacy/Controlled Substance Exp.1/31/2007
1997- U.S. Department of Justice DEA License Exp. 2/28/2007
1996- American Board of Internal Medicine -- Certified in Internal Medicine,
1996-2006
1999- American Board of Internal Medicine -- Certified in Pulmonary Medicine, 1999-2009. Recertified 2009-2019
2002- American Board of Internal Medicine -- Certified in Critical Care Medicine, 2002-2012
Academic, Administrative, and Clinical Appointments
Academic Appointments:
7/1998 – 9/2002 Lecturer, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI
9/2002 - 2008 Assistant Professor, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI
9/2008-present Clinical Associate Professor, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI
Administrative Duties:
2007-2009 Basic Science Academic Review Board
2007-2011 Pulmonary Inpatient Service Director
2011-present Basic Science Academic Review Board
2008-present Director of M2 Respiratory Sequence
2011-present Assistant Director of Internal Medicine Clerkship
Research Interests
- The role of PAI-1 in pulmonary fibrosis.
- The role of the plasminogen system and HGF in skeletal muscle repair.
- The role of alveolar epithelial cell injury in lung disease pathogenesis.
Grants
Summary of Major Previous Grants:
NIH/NHLBI R01-HL-06-5455
The Anti-protease and Vitronectin-binding Functions of PAI-1 in Lung Fibrosis
P.I.: Thomas H. Sisson, M.D. (50% effort)
04/01/07 – 03/31/12 ($250,000 annual direct costs)
NIH/NHLBI RFA-HL-06-5474
Apoptotic T Cell Clearance from Murine Lungs
P.I.: Jeffrey L. Curtis, M.D.
Role: Co-Investigator (10% effort)
04/01/07 – 03/31/11 ($225,000 annual direct costs)
American Lung Association of Michigan
P.I.: T. Sisson
Fibrinolytic Gene Transfer to Limit Fibrosis from Lung Inflammation
07/01/97-06/30/98 ($32,500 total direct costs)
NIH/NHLBI, T32 HL07749 – 05 – 06
P.D.: G. Toews; Co-I: T. Sisson
Multidisciplinary Training Program in Lung Disease
Stipend 06/30/98 – 06/29/00
Department of Defense, University of Chicago
Enhancement of Skeletal Muscle Repair by the
Urokinase-type Plasminogen Activator System
P.I.: T. Sisson – subcontract (10% effort)
01/01/05 – 12/31/08 ($84,082 annual direct costs)
FAMRI – 04 – 06
Flight Attendant Medical Research Institute
A Transgenic Animal Model to Control the Angiogenic Switch in Lung Cancer
P.I.: D. Arenberg; Co-I: T. Sisson (5% effort)
07/01/04-6/30/08 ($0 annual direct cost) (no cost)
NIH/NHLBI U10-HL-07-4422
Strategies to Prevent Chronic Obstructive Pulmonary Disease (COPD) Exacerbation (COPD Clinical Research Network)
P.I.: Fernando J. Martinez, MD, MS
Role: Co-Investigator (5% effort)
(Effort for Thomas H. Sisson, MD began on 07/01/06)
9/28/04-8/31/07 ($294,688 annual direct costs)
ALA – RG1081N
American Lung Association
The Role of the Plasminogen System in the Pathogenesis of Emphysema
P.I.: T. Sisson (5% effort)
07/01/04-06/30/06 ($35,000 annual direct costs)
NIH/NHLBI, K08 HL04434
Plasmin, Fibrin, and Metalloproteinases in Lung Fibrosis
P.I.: T. Sisson (80% effort)
07/1/00 – 06/30/05 ($620,000 total direct costs)
Honors and Awards
1985 Golden Key Honor Society
1988-89 Basic Science Honors: Gross Anatomy, Histology, Neuro-Behavioral Science, Genetics, Microbiology, Pharmacology
1991-92 Clinical Science Honors: Psychiatry, Dermatology, Neurology, Internal Medicine
1992 AOA
1992 Pulmonary and Critical Care Award at Senior Honor Convocation
1993 Golden Beeper Student Teaching Award
2002 Internal Medicine Student Teaching Award
2004 Richard D. Judge Award for Excellence in Student Teaching
2007 Galen’s Medical Society Silver Shovel Award
2009 Kaiser-Permanente Award for Excellence in Teaching in Pre-Clinical Sciences.
2013 Election into The League of Educational Excellence
Memberships in Professional Societies
1988-1989 Phi Delta Epsilon
1988-1992 Phi Rho Sigma Medical Society; President, 1989
1988-1992 American Medical Association
1991-1992 Galens Medical Society
1995-present American Thoracic Society
2004-2006 Honorary Faculty Member of Galen’s Medical Society
2004-present President of Phi Rho Sigma Alumni Board
2008-2010 Honorary Faculty Member of Galen’s Medical Society
2011-present Honorary Faculty Member of Galen’s Medical Society
Teaching
University of Michigan
11/21/97 Pulmonary Research Conference, "Upregulation of Alveolar Fibrinolytic Activity to Prevent Pulmonary Fibrosis Through Gene Therapy," University of Michigan, Ann Arbor, MI
1998 Internal Medicine Noon Conference, "Acute Respiratory Distress Syndrome," University of Michigan, Ann Arbor, MI
1999 Pulmonary Clinical Conference, "Current Management of Cystic Fibrosis," University of Michigan, Ann Arbor, MI
1999 Internal Medicine Noon Conference, "Upregulation of Lung uPA Activity to Treat Pulmonary Fibrosis," University of Michigan, Ann Arbor, MI
1/22/99 Pulmonary Research Conference, "The Role of Alveolar Fibrinolytic Activity in the Development of Pulmonary Fibrosis," University of Michigan, Ann Arbor, MI
2000 Internal Medicine Noon Conference, "Management of Sepsis," University of Michigan, Ann Arbor, MI
2000 Internal Medicine Noon Conference, "Pulmonary Artery Catheterization," University of Michigan, Ann Arbor, MI
2002 Internal Medicine Continuing Medical Education, "Controversies in the Use of the Pulmonary Artery Catheter"
3/31/00 Pulmonary Research Conference, "The Role of the Plasminogen Activator System in Pulmonary Fibrosis", University of Michigan, Ann Arbor, MI
7/20/00 Pulmonary Clinical Conference, "Management of Sepsis," University of Michigan, Ann Arbor, MI
1/19/2001 Pulmonary Research Conference, "The Role of the Plasminogen Activator System in Pulmonary Fibrosis," University of Michigan, Ann Arbor, MI
05/2002 Pulmonary Clinical Conference, “Pathophysiology and Treatment of Cystic Fibrosis Lung Disease”, University of Michigan, Ann Arbor, MI
01/2003 Pulmonary Clinical Conference, “Disseminated Intravascular Coagulation”, University of Michigan, Ann Arbor, MI
03/2003 Pulmonary Research Conference, “Plasminogen Activation and Pulmonary Fibrosis” University of Michigan, Ann Arbor, MI
09/2004 Pulmonary Research Conference, "The Plasminogen Activator System in Pulmonary Fibrosis," University of Michigan, Ann Arbor, MI
01/2005 Pulmonary Clinical Conference, “Update on the Treatment of Cystic Fibrosis Lung Disease”, University of Michigan, Ann Arbor, MI
07/2005 Pulmonary Research Conference, “The Contribution of Vitronectin to PAI-1’s Pro-Fibrotic Effect”, University of Michigan, Ann Arbor, MI
10/2005 Pulmonary Fellows Conference, “Clinical Journal Club”, University of Michigan, Ann Arbor, MI
11/2005 Pulmonary Fellows Conference, “Clinical Journal Club”, University of Michigan, Ann Arbor, MI
11/2005 Pulmonary Fellows Conference, “Clinical Journal Club” “Interesting Cases”, University of Michigan, Ann Arbor, MI
11/2005 Pulmonary Fellows Conference, “Clinical Journal Club” “Interesting Cases”, University of Michigan, Ann Arbor, MI
1998-2004 Clinical Skills Instructor, University of Michigan, Ann Arbor, MI
1999-2005 Pulmonary Exam Instructor, University of Michigan, Ann Arbor, MI
2003-present M2 Respiratory Sequence, ARDS, Mechanical Ventilation, and Pulmonary Vasculatr Disease. University of Michigan, Ann Arbor, MI
2001-Present Instructor for Clinical Foundations of Medicine (10% Effort)
2004-Present Instructor for the Family Centered Experience and Longitudinal Case Studies (10% Effort)
2007-Present M1 Cardiorespiratory Sequence. 3 lectures on pulmonary physiology.
2007-Present M2 Respiratory Sequence Co-director.
2007-Present PSIP Team Leader for Internal Medicine House Officer Program
Attending Physician University of Michigan
1998 Pulmonary Inpatient Attending Physician
1999 VA Consult Attending Physician 1 mo/yr; Pulmonary Inpatient Attending Physician 2 mo/yr
2000 VA Consult Attending Physician
2001-present Pulmonary Inpatient attending and CCMU attending 2.5 mo/year
2009-2010 Development of Pulmonary Cases for Physician Skill Builder Program
Committee, Organizational, and Volunteer Service
Institutional:
2005-Present CCA Exam Committee Member
2006-present GME Innovations Fund Proposal/Patient Safety Initiative
2007-present Summer Biomedical Research Program Committee Member
2007-Present Fellowship Education Committee Member
2009-2010 Anatomy Review Committee Member
2007-Present Admission Executive Committee Member
2007-Present Infection Control Committee
Visiting Professorships, Seminars, and Extramural Invited Presentations
Extramural Invited Presentations:
2000 Invited Speaker to Michigan Society of Respiratory Therapy, "Current Management of Cystic Fibrosis," Frankenmuth, MI
2005-06 Round table Speaker NACF Conference, “Aspergillus in Cystic Fibrosis Lung Disease”, Baltimore, Maryland
2006 Invited Speaker to the Cystic Fibrosis Care Givers Meeting at Children’s Hospital, “The Value of Genotyping Patients with Cystic Fibrosis”. Detroit, Michigan.
2011 St. Mary’s Hospital Internal Medicine Grand Rounds, “Adult Cystic Fibrosis” Grosse Pointe, Michigan.
Bibliography
Peer-Reviewed Journals and Publications:
1. Sisson TH, Castor, CW. An improved method for immobilizing IgG on protein A-agarose. Immunol Methods 1990; 127:215-220, PMID: 2313100
2. Castor CW, Smith EM, Bignall MC, Hossler PA, Sisson TH. Preparation and Bioassay of Connective Tissue Activating Peptide III and its Isoforms. Methods Enzymol 1991;198;405-16 PMID: 1857233
3. Hattori N, Sisson TH, Xu Y, Simon RH. Upregulation of fibrinolysis by adenovirus-mediated transfer of urokinase-type plasminogen activator genes to lung cells in vitro and in vivo. Hum Gene Ther 1999; 10:215-222, PMID: 10022546
4. Hattori N, Sisson TH, Xu Y, Desai TJ, Simon RH. Participation of urokinase-type plasminogen activator receptor in the clearance of fibrin from the lung. Am J Physiol Lung 1999; 277:L573-L579, PMID: 10484465
5. Standiford TJ, Wilkowski JM, Sisson TH, Hattori N, Bucknell KA, Moore TA. Intrapulmonary TNF gene therapy enhances antibacterial host defense in murine gram-negative bacterial pneumonia. Human Gene Therapy 1999; 10:899-909 PMID: 10223724
6. Sisson TH, Hattori N, Xu Y, Simon RH. Treatment of Bleomycin-induced Pulmonary Fibrosis by Transfer of Urokinase-type Plasminogen Activator Genes. Hum Gene Ther 1999; 10(14)2315-2323, PMID: 10515451
7. Hattori N, Degen JL, Sisson TH, Liu H, Moore BB, Pandrangi RG, Simon RH, Drew AF. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000; 106:1341-1350, PMCID: PMC381464
8. Sisson TH, Hanson KE, Subbotina N, Patwardhan A, Hattori N, Simon RH. Inducible lung specific urokinase expression improves survival after inflammatory lung injury in mice. Am J Physiol Lung Cell Mol Physiol 2002; 283:L1023-32, PMID: 12376355
9. Kim KK, Flaherty KR, Long Qi, Hattori N, Sisson TH, Colby TV, Travis WD, Martinez FJ, Murray S, Simon RH. A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia. Mol Med 2003; 9:52-56, PMCID: PMC 1430380
10. Chuang-Tsai S, Sisson TH, Hattori N, Tsai CG, Subbotina NM, Hanson KE, Simon RH. Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am J Pathol. 2003 Aug; 163(2):445-52, PMCID: PMC1868204
11. Hattori N, Mizuno S, Yoshida Y, Chin K, Mishima M, Sisson TH, Simon RH, Nakamura T, Miyake M. The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Am J Pathol. 2004 Mar; 164(3):1091-8, PMCID: PMC1614722
12. Lazar MH, Christensen PJ, Hanson KE, Hansen JM, White ES, Simon RH, Sisson TH. Plasminogen Activator Inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. Am J Respir Cell Mol Biol. 2004 Dec; 31(6):672-8, PMID: 15308506
13. Nishiuma T, Sisson TH, Subbotina N, Simon RH. Localization of plasminogen activator activity within normal and injured lungs by in situ zymography. Am J Respir Cell Mol Biol. 2004 Nov; 31(5):552-8, PMID: 1528478
14. Sisson TH, Simon RH. Cell specific control of coagulation and fibrinolysis within the lung. Thromb Haemost. 2004 Sep;92(3):435-7, PMID: 15351836
15. Koh TJ, Bryer SC, Pucci AM, Sisson TH. Mice Deficient in Plasminogen Activator Inhibitor-1 Improved Skeletal Muscle Regeneration. Am J Physiol Cell Physiol. 2005 Jul;289(1):C217-23, PMID 15716324
16. Sisson TH, Hansen JM, Shah M, Hanson KE, Du M, Ling T, Simon RH, Christensen PJ. Expression of the reverse tetracycline-transactivator gene causes emphysema-like changes in mice. Am J Respir Cell Mol Biol. 2006 May;34(5):552-60, PMCID: PMC2644220
17. Matsuoka H, Sisson TH, Nishiuma T, Simon RH. Plasminogen-mediated activation and release of hepatocyte growth factor from extracellular matrix. Am J Respir Cell Mol Biol. 2006 Dec;35(6):705-13, PMCID:PMC2643296
18. Horowitz JC, Rogers DS, Simon RH, Sisson TH, Thannickal VJ. Plasminogen Activation-Induced Pericellular Fibronectin Proteolysis Promotes Fibroblast Apoptosis. Am J Respir Cell Mol Biol. 2008 38(1):78-87, PMCID: PMC2176129
19. Sisson TH, Simon RH. The Plasminogen Activation System in Lung Disease. Current Drug Targets. 2007;8(9):1016-29, PMID: 17896953 NIHMSID # 316036
20. Kuramoto E, Nishiuma T, Kobayashi K, Yamamoto M, Kono Y, Funada Y, Kotani Y, Sisson TH, Simon RH, Nishimura Y. Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model. Am J Physiol Lung Cell Mol Physiol. 2009;296(3):L337-46, NIHMSID #316035
21. Humphries J, Gossage JA, Modarai B, Burnand KG, Sisson TH, Murdoch C, and Smith A. Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis. J Vasc Surg. 2009;50(5):1127-34, PMCID: PMC2778796
22. Sisson TH, Nguyen MH, Yu B, Simon RH, Koh TJ. Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration. Blood. 200;114(24):5052-61, PMCID: PMC2788978
23. Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, Cunningham A, Dave A, Engelhardt JF, Liu X, White ES, Thannickal VJ, Moore BB, Christensen PJ, Simon RH. Targeted Injury of Type II Alveolar Epithelial Cells Induces Pulmonary Fibrosis. Am J Respir Crit Care Med. 201;181(3):254-63, PMCID: PMC2817814
24. Bauman KA, Scott H. Wettlaufer SH, Vannella KM, Stoolman JS, Huang SK, Kovalszki A, White ES, Hogaboam CM, Simon RH, Sisson TH, Moore BB, and Peters-Golden M. Anti-Fibrotic Actions of Plasminogen Activation are Mediated via Upregulation of Prostaglandin E2 Synthesis. J Clin Invest 2010;120(6):1950-60. PMCID: PMC2877926
25. Stoolman JS, Vannella KM, Coomes SM, Wilke CA, Sisson TH, Toews GB, and Moore BB. Latent Infection by Gammaherpesvirus Stimulates Pro-fibrotic Mediator Release from Multiple Cell Types. AJP-lung.Am J Physiol Lung Cell Mol Physiol. 2011; 300(2):L274-85, PMCID 3043816